News from IMIM
A scientific team led by Esther Barreiro has conducted a study on mice to test the improvements that can be obtained from the combination of several treatments in non-small cell lung cancer. Lung cancer is the deadliest in the world, being the cause of more than one and half million deaths a year. Of all lung cancers, adenocarcinoma is the most common subtype. The presence of other underlying affectations, such as chronic obstructive pulmonary disease (COPD), which also involves high mortality in industrialized regions, causes an increased risk. Despite recent progress in therapeutic strategies to fight this disease, most patients who are diagnosed do not exceed five years.
Bortezomib is a drug commonly used to treat multiple myeloma and certain types of lymphoma. It inhibits the proteasome, a cell organelle in charge of destroying residual proteins. Despite being widely used, bortezomib is ineffective when used alone. However, if additional means are used to inhibit tumor growth, then tumor death occurs and cell proliferation stops.
Mateu-Jimenez M, Fermoselle C, Rojo F, Mateu J, Peña R, Urtreger AJ, Diament MJ, de Kier Joffé ED, Pijuan L, de Herreros AG, Barreiro E. Pharmacological Approaches in an Experimental Model of Non-Small Cell Lung Cancer: Effects on Tumor Biology. Current Pharmaceutical Design, Junio 2016.